Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a buy rating and set a $7.00 price target on shares of Aptose Biosciences in a research report on Friday, June 14th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Aptose Biosciences has a consensus rating of Moderate Buy and an average price target of $9.00.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.36 on Friday. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.32. The stock has a market cap of $6.50 million, a PE ratio of -0.06 and a beta of 1.26. The stock has a fifty day moving average of $0.43 and a 200-day moving average of $0.83.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.15. On average, sell-side analysts predict that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.